Health Condition 1: B690- Cysticercosis of central nervous system
Conditions
Interventions
Intervention1: Fourteen days Albendazole therapy: Albendazole (15 mg/kg/day) for 14 days plus standard treatment, maximum daily dose being 800 mg.
Control Intervention1: Twenty eight days Albendazole
Sponsors
Narain Das Vaswani
Eligibility
Inclusion criteria
Inclusion criteria: Children aged 1-14 years newly diagnosed with active neurocysticercosis will be enrolled.
Exclusion criteria
Exclusion criteria: 1. Children who have received albendazole or diagnosed with NCC in preceding 3 months. 2. Children with intellectual disability or global developmental delay, coexisting neurodegenerative/neurometabolic or any other structural pathology. 3. Children with recognized progressive neurological illness. 4. Children with renal, pulmonary, cardiac or hepatic dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of children with resolution of active lesion (Active lesion was considered to be resolved when either there was complete disappearance of lesion or when T2 hyperintensity within the core of the lesion has become either isointense or hypointense with or without blooming effect on GRE image) at 6 month follow up scan.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration to seizure recurrenceTimepoint: One week to six months | — |
Countries
India
Contacts
Public ContactAnkit Singla
Pt. B.D. Sharma PGIMS Rohtak
Outcome results
None listed